Piotr Wysocki: Dostarlimab combined with chemotherapy in dMMR/MSI-H advanced endometrial cancer patietns

Piotr Wysocki recently posted on LinkedIn:

“Part 1 of the RUBY trial (NCT03981796) evaluated the benefit of adding dostarlimab or placebo to standard first-line chemotherapy in patients with primary advanced or recurrent endometrial cancer. The study randomized 494 patients (1:1) to dostarlimab+carboplatin+paclitaxel (CP) or placebo+CP administered for 6 cycles, with maintenance dostarlimab or placebo administered for up to 3 years.

In the second intermin analysis, the study met the dual-primary endpoint for OS. In the general population, combining dostarlimab with CP significantly reduced the relative risk of death by 31% (HR=0.69; 95%CI 0.54-0.89).

The significant improvement in OS in the ITT population was driven by the benefit of dostarlimab in patients with dMMR/MSI-H tumors, where dostarlimab reduced the relative risk of death by 68% (HR=0.32; 95% CI 0.17-0.63).

Patients with pMMR/MSI-L tumors did not demonstrate significant improvement in OS (HR=0.79; 95% CI 0.60-1.04).

Despite significant improvement of PFS in both dMMR/MSI-H and pMMR/MSI-L populations, dostarlimab does not improve long-term outcomes in patients with advanced pMMR/MSI-L endometrial tumors.”

Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial

Authors: M.A. Powell, L. Bjørge, L. Willmott, Z. Novák, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L.M. Landrum, M. Gropp-Meier, A. Stuckey, I. Boere, M.A. Gold, Y. Segev, S.E. Gill, C. Gennigens, A. Sebastianelli, M.S. Shahin, B. Pothuri, B.J. Monk, J. Buscema, R.L. Coleman, B.M. Slomovitz, K.L. Ring, T.J. Herzog, M. Marco Balas, Ma. Grimshaw, S. Stevens, D.W. Lai, C. McCourt, M.R. Mirza

Source: Piotr Wysocki/LinkedIn

Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.

His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.

Read other posts by Piotr Wysocki published on OncoDaily.